首页> 外文期刊>JAMA: the Journal of the American Medical Association >Zolpidem-related surge in emergency department visits
【24h】

Zolpidem-related surge in emergency department visits

机译:与唑吡坦有关的急诊就诊激增

获取原文
获取原文并翻译 | 示例
       

摘要

EMERGENCY DEPARTMENT VISITS IN-volving adverse reactions to the sleep medication Zolpidem increased 220% from 2005 to 2010, from 6111 visits to 19 487 visits, said the authors of a report issued May 1 by the Substance Abuse and Mental Health Services Administration (SAMHSA). Nearly 3 in 4 zolpidem-related emergency department visits involved patients aged 45 years or older, and roughly two-thirds were women. An estimated 50 million to 70 million people in,the United States have-chronic sleep disorders. Zolpidem, a sedative-hfp-notic medicine, was approved by the Food and Drug Administration (FDA) in 1992 for the short-term treatment of insomnia and is the active ingredient in such drugs as Ambien, Ambien CR, Edluar, and Zolpimist.
机译:药物滥用和精神卫生服务管理局(SAMHSA)在5月1日发布的报告的作者说,从2005年到2010年,急诊部对涉及睡眠药物Zolpidem的不良反应增加了220%,从6111次到19 487次。 。与唑吡坦相关的急诊科中,有近四分之三的患者年龄在45岁或以上,约三分之二是女性。在美国,估计有5000万至7000万人患有慢性睡眠障碍。 Zolpidem是一种镇静性hfp药物,于1992年被食品药品监督管理局(FDA)批准用于失眠的短期治疗,并且是Ambien,Ambien CR,Edluar和Zolpimist等药物的有效成分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号